Neuronetics Reports 99% Revenue Growth Driven by Acquisition, Faces Margin Pressure, Debt Covenant Waivers, and CEO Transition

summarizeSummary

Neuronetics' annual report reveals substantial revenue growth in 2025, primarily due to the Greenbrook acquisition, but this came with a significant reduction in gross margins. The company continues to operate at a net loss and relies on dilutive equity financing and debt amendments to manage its liquidity. The waiver of 'going concern' language for 2025 and 2026 financial statements, along with ongoing legal investigations, highlights persistent financial and operational challenges. The change in CEO and a major shareholder's intent to sell shares add further uncertainty.

check_boxKey Events

• Strong Revenue Growth Driven by Acquisition

  Total revenues increased by 99% to $149.2 million for the year ended December 31, 2025, up from $74.9 million in 2024. This growth was primarily attributable to the acquisition of Greenbrook in December 2024, which significantly shifted the U.S. revenue mix, with clinic revenue now representing 59% of U.S. revenues compared to 6% in the prior year.

• Reduced Net Loss Amidst Significant Margin Compression

  The company reported a net loss of $39.1 million for 2025, an improvement from a $43.7 million net loss in 2024. However, gross margin decreased substantially to 48.5% in 2025 from 72.3% in 2024, primarily due to the inclusion of Greenbrook's clinic business and a reduction in treatment session revenue.

• Debt Covenant Waivers and Principal Payment

  On March 12, 2026, Neuronetics amended its Perceptive Credit Facility to modify revenue and liquidity covenants and made a one-time principal payment of $5.0 million. Critically, the Administrative Agent and Majority Lender waived compliance with the 'No Qualification Requirement' regarding 'going concern' language for financial statements covering fiscal year 2025 and periods within 2026.

• Executive Leadership Transition

  Daniel L. Reuvers has been appointed as the new President and Chief Executive Officer, effective March 23, 2026, succeeding Keith J. Sullivan, who will retire on March 31, 2026. Mr. Reuvers will receive an initial annual base salary of $730,000 and a grant of 1,500,000 restricted stock units.

auto_awesomeAnalysis

Neuronetics' annual report reveals substantial revenue growth in 2025, primarily due to the Greenbrook acquisition, but this came with a significant reduction in gross margins. The company continues to operate at a net loss and relies on dilutive equity financing and debt amendments to manage its liquidity. The waiver of 'going concern' language for 2025 and 2026 financial statements, along with ongoing legal investigations, highlights persistent financial and operational challenges. The change in CEO and a major shareholder's intent to sell shares add further uncertainty.